Clinical considerations in the management of the menopause: the endometrium.
Exogenous oestrogens prescribed for the relief of menopausal symptoms are being given in pharmacological doses and the term 'hormone replacement therapy' is inappropriate. The frequent development of endometrial hyperplasia during unopposed cyclical oestrogen therapy is therefore to be expected, but no single pattern of vaginal bleeding accurately reflected the histology of the endometrium. As such doses of oestrogens are required for effective relief of symptoms, progestogens must be given to protect against endometrial hyperstimulation. Patient acceptability of sequential oestrogen/progestogen therapy is high (90%) and with such therapy breakthrough bleeding may subsequently be shown to be a reliable indicator of underlying endometrial pathology.
D004714:Endometrial Hyperplasia / Q000139:chemically induced / Q000378:metabolism; D004967:Estrogens / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D010342:Patient Acceptance of Health Care; D045167:Progesterone Congeners / Q000627:therapeutic use*; D014592:Uterine Hemorrhage / Q000139:chemically induced / Q000378:metabolism
D004967:Estrogens; D045167:Progesterone Congeners